Canada-based biotech firm Willow Biosciences (TSX: WLLW) (OTCQB: CANSF) this week reported a net loss of C$6.1 million despite posting a roughly threefold increase in revenue in 2024. The company also appears poised to close down entirely, with operations slated to cease as soon as the sale of a subsidiary…
Please login to read all 257 words.
